• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人体注射 89Zr 标记单克隆抗体的剂量学评估。

Dosimetry Assessment of Injected 89Zr-Labeled Monoclonal Antibodies in Humans.

机构信息

a Ural Federal University, Ekaterinburg, Russia.

c Physics Department, Faculty of Science, Al-Azhar University, Assuit Branch, Assuit, Egypt.

出版信息

Radiat Res. 2019 May;191(5):466-474. doi: 10.1667/RR15321.1. Epub 2019 Mar 21.

DOI:10.1667/RR15321.1
PMID:30896281
Abstract

In this study, the behavior dynamics of Zirconium-89 (Zr)-labeled monoclonal antibodies (MAbs) after injection into the human body were modeled. This modified biokinetic model can be used for dose assessment, not only for Zr-labeled MAb tumor visualization, but also for diagnostic and therapeutic radiation with MAb labeled with other radionuclides. A modified biokinetic model was created based on experimental data from previously published studies. Cumulative Zr activity in organs and tissues per Bq of administered activity was calculated using the WinAct program. For most organs receiving the highest radiation dose, average absorbed doses were estimated using IDAC version 2.1 software. The results from the modeled calculations were compared with recently published results from studies of real patients. The calculations revealed that organs with the highest dose were the spleen, liver, kidneys and red bone marrow, at 1.54, 1.33, 0.81 and 0.82 mGy/MBq, respectively. In the modified biokinetic model, with MAb injection, organs exhibiting the highest dose were liver, heart wall, spleen, red bone marrow and pancreas, at 1.05, 0.93, 0.79, 0.69 and 0.67 mGy/MBq, respectively.

摘要

在这项研究中,模拟了注射入人体后的 89 锆(Zr)标记单克隆抗体(Mab)的行为动力学。这种改良的生物动力学模型可用于剂量评估,不仅可用于 Zr 标记的 Mab 肿瘤可视化,还可用于其他放射性核素标记的 Mab 的诊断和治疗辐射。基于先前发表的研究中的实验数据创建了改良的生物动力学模型。使用 WinAct 程序计算每 Bq 给予的活性的器官和组织中累积的 Zr 活性。对于接受最高辐射剂量的大多数器官,使用 IDAC 版本 2.1 软件估算平均吸收剂量。将模型计算的结果与最近发表的真实患者研究结果进行了比较。计算结果表明,剂量最高的器官是脾脏、肝脏、肾脏和红骨髓,分别为 1.54、1.33、0.81 和 0.82 mGy/MBq。在改良的生物动力学模型中,注射 Mab 后,肝脏、心脏壁、脾脏、红骨髓和胰腺的器官显示出最高的剂量,分别为 1.05、0.93、0.79、0.69 和 0.67 mGy/MBq。

相似文献

1
Dosimetry Assessment of Injected 89Zr-Labeled Monoclonal Antibodies in Humans.人体注射 89Zr 标记单克隆抗体的剂量学评估。
Radiat Res. 2019 May;191(5):466-474. doi: 10.1667/RR15321.1. Epub 2019 Mar 21.
2
Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.用于头颈癌患者免疫正电子发射断层显像的89Zr标记嵌合单克隆抗体U36的辐射剂量测定
J Nucl Med. 2009 Nov;50(11):1828-36. doi: 10.2967/jnumed.109.065862. Epub 2009 Oct 16.
3
Assessment of absorbed dose for Zr-89, Sm-153 and Lu-177 medical radioisotopes: IDAC-Dose2.1 and OLINDA experience.评估 Zr-89、Sm-153 和 Lu-177 医用放射性同位素的吸收剂量:IDAC-Dose2.1 和 OLINDA 经验。
Appl Radiat Isot. 2021 Oct;176:109841. doi: 10.1016/j.apradiso.2021.109841. Epub 2021 Jun 26.
4
Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET.90Y-替伊莫单抗替曲昔肽治疗复发性 B 细胞非霍奇金淋巴瘤患者的生物分布、辐射剂量学和初步研究:使用 89Zr-替伊莫单抗替曲昔肽和 PET。
Eur J Nucl Med Mol Imaging. 2012 Mar;39(3):512-20. doi: 10.1007/s00259-011-2008-5. Epub 2012 Jan 5.
5
Assessment of exposure after injection of Tc-labeled intact monoclonal antibodies and their fragments into humans.注射锝标记的完整单克隆抗体及其片段后人体暴露情况的评估。
Radiol Phys Technol. 2019 Mar;12(1):96-104. doi: 10.1007/s12194-018-00496-1. Epub 2019 Jan 2.
6
Radiolabeling, biodistribution, and dosimetry of (123)I-mAb 14C5: a new mAb for radioimmunodetection of tumor growth and metastasis in vivo.(123)I标记的单克隆抗体14C5的放射性标记、生物分布及剂量测定:一种用于体内肿瘤生长和转移放射免疫检测的新型单克隆抗体
J Nucl Med. 2004 Jun;45(6):1065-73.
7
Evaluation of PET/CT imaging with [89Zr]Zr-DFO-girentuximab: a phase 1 clinical study in Japanese patients with renal cell carcinoma (Zirdac-JP).[89Zr]Zr-DFO-girentuximab 的 PET/CT 成像评估:日本肾细胞癌患者的 1 期临床研究(Zirdac-JP)。
Jpn J Clin Oncol. 2024 Aug 14;54(8):873-879. doi: 10.1093/jjco/hyae075.
8
PET/CT-derived whole-body and bone marrow dosimetry of 89Zr-cetuximab.89Zr-西妥昔单抗的PET/CT全身及骨髓剂量测定
J Nucl Med. 2015 Feb;56(2):249-54. doi: 10.2967/jnumed.114.147819. Epub 2015 Jan 22.
9
Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.利妥昔单抗治疗对非霍奇金淋巴瘤患者 90Y-替伊莫单抗剂量学的影响。
J Nucl Med. 2010 Jan;51(1):150-7. doi: 10.2967/jnumed.109.066597. Epub 2009 Dec 15.
10
89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.89Zr免疫正电子发射断层显像:89Zr标记单克隆抗体的综合制备程序
J Nucl Med. 2003 Aug;44(8):1271-81.

引用本文的文献

1
Exploring the Potential of Zirconium-89 in Diagnostic Radiopharmaceutical Applications: An Analytical Investigation.探索锆-89在诊断放射性药物应用中的潜力:一项分析研究。
Biomedicines. 2023 Apr 13;11(4):1173. doi: 10.3390/biomedicines11041173.
2
Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis.用于PD-1/PD-L1轴成像的放射性示踪剂的研发
Pharmaceuticals (Basel). 2022 Jun 14;15(6):747. doi: 10.3390/ph15060747.
3
PET/CT Imaging of Zr-N-sucDf-Pembrolizumab in Healthy Cynomolgus Monkeys.Zr-N-sucDf-Pembrolizumab 的健康食蟹猴 PET/CT 成像研究。
Mol Imaging Biol. 2021 Apr;23(2):250-259. doi: 10.1007/s11307-020-01558-w. Epub 2020 Oct 26.